Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.67 |
| ▸ | CNR1 | P21554 | 8/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | LPAR6 | P43657 | 2/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.49 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.49 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.49 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.49 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28396798 | 1.00 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL2216579 | 1.00 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL2217627 | 1.00 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL29511938 | 1.00 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL100166 | 1.00 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL3793537 | 1.00 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL9243523 | 1.00 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL2218924 | 1.00 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL6417540 | 1.00 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL2340727 | 1.00 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011106194-A2 | PROCESS FOR MAKING POLYOL ETHERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2011-09-01 | — | — | WO | disclosed |
| US-20110207969-A1 | PROCESS FOR MAKING POLYOL ETHERS | DOW GLOBAL TECHNOLOGIES LLC | 2011-08-25 | — | — | US | disclosed |
| US-4803010-A | ADDUCT OF ETHYLENE OXIDE, POLYHYDRIC ALCOHOL AND FATTY ACID | KAO CORPORATION (JP) | 1989-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207969-A1 | PROCESS FOR MAKING POLYOL ETHERS | PUF60, PARG, PCBP1 | CNR2 2528/4885CNR1 2802/4885ALDH1A1 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.